Biogen agreed to acquire RayThera in a deal that could total as much as $1 billion, giving the neurology-focused company access to early-stage immunology assets. The portfolio centers on anti-inflammatory drug candidates, including a prospect slated to enter the clinic in the third quarter. RayThera, founded in 2023, disclosed few technical pipeline details publicly before the acquisition, but its funding history and target hints suggested exploration of established immunology pathways such as TNF activity modulation, STAT6 and other signaling nodes. The deal structure is backloaded, with investors receiving an undisclosed upfront payment and potential additional consideration tied to unspecified clinical and regulatory goals. Biogen positioned the transaction as a step to fill earlier stages of its pipeline after the Apellis Pharmaceuticals purchase. The RayThera acquisition further reinforces Biogen’s push to broaden beyond its historic strength in neurology and into immunology. For investors and competitors, the RayThera deal signals that large-cap biopharma continues to pay for early discovery and preclinical-stage immunology platforms, even when target specifics are initially limited in public disclosure.